Igor Smolenov

ResearcherID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 2

Top Topics

Respiratory Syncytial Virus

Placebo Controlled

Top Venues

Human vaccines & immunotherapeutics

Seqirus (United States)

Volgograd State Medical University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Seqirus (United States)

United States

TA Head :: Clinical Development

Education History

Volgograd State Medical University

Russia

PHD :: Clinical Pharmacology

Publications

Pio Lopez, Lulu Bravo, Erik Buntinx, Charissa Borja-Tabora, Hector Velasquez, Edith Johana Rodriquez, Camilo A Rodriguez, Josefina Carlos, May Emmeline B Montellano, Edison R Alberto, Milagros Salvani-Bautista, Yung Huang, Branda Hu, Ping Li, Htay Htay Han, Carmen Baccarini, Igor Smolenov
Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12-17 year-old adolescents. Human vaccines & immunotherapeutics (2023)
Antonios O Aliprantis, Christine A Shaw, Paul Griffin, Nicholas Farinola, Radha A Railkar, Xin Cao, Wen Liu, Jeffrey R Sachs, Christine J Swenson, Heather Lee, Kara S Cox, Daniel S Spellman, Colleen J Winstead, Igor Smolenov, Eseng Lai, Tal Zaks, Amy S Espeseth, Lori Panther
A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults. Human vaccines & immunotherapeutics 17 (5) (2020)